RVL-1201
Phase 3Small molecule
RVL-1201 is one of 12 small molecule programs targeting Ptosis. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Ptosis
#DrugCompanyPhaseTrials
1Propecia
OOrganon and Co
Approved
Marcaine
IInnocoll
Approved
Venclexta
AbbViePhase 2
Ibrance
PfizerPhase 2
Perjeta
RochePhase 2
Eicosapentaenoic Acid
SS.L.A. Pharma AG
Phase 3
TEPEZZA
HHorizon Therapeutics Ireland DAC
Phase 3
Herceptin
OOrganon and Co
Phase 2
Faslodex
FFresenius Kabi Oncology Ltd.
Phase 2
RVL-1201
RRVL Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ptosis4 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RVL-1201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRVL Pharmaceuticals, Inc.